<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>NATCOPHARM</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">NATCOPHARM</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="natco-pharma-limited" class="section level1">
<h1>Natco Pharma Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.NATCOPHARM.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="natco-pharma-limited-natcopharm-analysis" class="section level3">
<h3>NATCO Pharma Limited (NATCOPHARM) Analysis</h3>
<p><strong>Date of Analysis</strong>: Based on Q2 FY26 earnings (quarter/half-year ended Sep 30, 2025), earnings call (Nov 14, 2025), financial results, board updates, AGM voting, and recent disclosures (e.g., FDA inspection Nov 21, 2025).</p>
<p>Natco Pharma, a generics-focused company with emphasis on complex/Para IV products (oncology, high-barrier molecules), operates in formulations (domestic/export), API, and Crop Health Sciences (CHS). FY26 H1 showed robust performance: consolidated revenue ₹2,692 Cr (+ve YoY trend), PAT ₹998 Cr (EPS ₹55.8), EBITDA margins ~46%. Balance sheet strong (net cash ~₹27,000 Cr in deposits/investments, assets ₹1.04 lakh Cr). Management guides FY26 PAT at ₹1,275-1,300 Cr (on track).</p>
<div id="headwinds" class="section level6">
<h6><strong>Headwinds</strong></h6>
<ul>
<li><strong>Revlimid/Lenalidomide Erosion</strong>: Q2 was peak; intense competition expected in Q3/Q4 FY26 and beyond. No aggressive budgeting for sales; ROW/US markets highly competitive post-patent expiry.</li>
<li><strong>Elevated Expenses</strong>: Q2 “other expenses” up due to bioequivalence R&amp;D (Para IV/clinical trials), one-time employee bonuses, inventory provisions, and patent litigation reserves. Impacted margins despite high EBITDA (46.4%).</li>
<li><strong>Regulatory Scrutiny</strong>: US FDA issued 7 procedural observations at Manali (Chennai) API unit (Nov 17-21, 2025 inspection). Company confident of resolution, but delays/risks in approvals/supply could arise (prior Kothur warning letter lifted, aiding Canada supplies).</li>
<li><strong>Crowded Generics Space</strong>: Para IV playbook now adopted by larger peers (e.g., “big five” Indian firms); domestic Semaglutide market competitive (Emcure/Novo in-licensed 9 months ahead).</li>
</ul>
</div>
<div id="tailwinds" class="section level6">
<h6><strong>Tailwinds</strong></h6>
<ul>
<li><strong>Adcock Ingram Acquisition</strong>: Completed Nov 11, 2025 (35.75% stake via SA sub for USD 225 Mn/ZAR 3,873 Mn). Steady PAT ~₹135-150 Cr/quarter from Q3 FY26; adds stable base (cough/cold portfolio), diversifies from volatile US generics (25-30% of future base earnings). Bought at 10-12x EBITDA (vs. India’s 30-40x).</li>
<li><strong>CHS Momentum</strong>: Q2 revenue ₹52 Cr (near EBITDA breakeven); combinations performing well. In-principle demerger approved (Sep 25, 2025); wholly-owned sub incorporated (Nov 14, 2025) for separate 2026 listing – unlocks pharma value, provides focus/flexibility.</li>
<li><strong>High Margins &amp; Cash Generation</strong>: OPM ~46%; H1 operating cash flow ₹1,181 Cr. Net cash hoard supports M&amp;A/dividends (₹1.5/share interim Q2; total FY26 ~₹7.5/share implied).</li>
<li><strong>ROW Stability</strong>: Brazil (first-to-generic Carfilzomib), Saudi, Canada ramping post-warning lift; offsets US slowdown.</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="27%" />
<col width="36%" />
<col width="36%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Opportunity</strong></th>
<th><strong>Timeline/Details</strong></th>
<th><strong>Potential Impact</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Semaglutide (Ozempic generic)</strong></td>
<td>Domestic: First-wave launch Mar/Apr 2026 (Phase III on track; file Jan 2026). US: FTF (subject to approval/litigation), 2-3 yrs away.</td>
<td>Domestic: +₹80-90 Cr (~20% domestic growth); ROW/US via Viatris JV. High-volume GLP-1 market despite competition.</td>
</tr>
<tr class="even">
<td><strong>Para IV Pipeline</strong></td>
<td>3-4 new filings H2 FY26; launches: 1-2 in FY27, bigger in FY27-28 (Ibrutinib, Olaparib, Erdafitinib). Risdiplam launched (doing well, niche neurology entry).</td>
<td>US/regulated markets jackpot potential; base +10-15% annual growth.</td>
</tr>
<tr class="odd">
<td><strong>Domestic Formulations</strong></td>
<td>Stable ₹105 Cr/Q; Semaglutide/Risdiplam to drive FY27+.</td>
<td>10-20% CAGR; oncology/neurology focus.</td>
</tr>
<tr class="even">
<td><strong>Exports/Subsidiaries</strong></td>
<td>Brazil/Canada/Saudi scaling; Viatris partnerships.</td>
<td>H1: ₹1,147 Cr/Q; stable post-Revlimid.</td>
</tr>
<tr class="odd">
<td><strong>CHS Demerger</strong></td>
<td>Listing 2026; retain minority stake + TSAs.</td>
<td>Value unlock; EBITDA positive trajectory.</td>
</tr>
<tr class="even">
<td><strong>M&amp;A/Investments</strong></td>
<td>Adcock integration; niche bets (e.g., eGenesis pig-kidney transplant, CAR-T).</td>
<td>Diversification; upside if breakthroughs.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Outlook</strong>: FY26 steady (PAT flat YoY due to Revlimid cliff); FY27+ acceleration via pipeline/Acquisitions. Base business ~10-15% growth; “jackpot” upside from FTFs.</p>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<ol style="list-style-type: decimal">
<li><strong>Pipeline Execution/Regulatory</strong>: Para IV success hinges on FTF status, litigation wins, FDA approvals. Semaglutide US delayed; FDA observations at API site.</li>
<li><strong>Competition &amp; Pricing</strong>: Revlimid/Semaglutide margins erode quickly; US dependency (~80% exports).</li>
<li><strong>Forex/Geo-Political</strong>: High US/ROW exposure; currency volatility (e.g., ZAR/USD in Adcock).</li>
<li><strong>Capex/Debt</strong>: Borrowings ~₹2,528 Cr; AGM approved Section 180 limits for expansion (98.7% approval). Demerger complexities.</li>
<li><strong>Valuation/Market Sentiment</strong>: Stock trades at premium for pipeline; demerger/M&amp;A integration risks. Provisions/litigation could surprise.</li>
<li><strong>Macro</strong>: R&amp;D intensity (~high single-digit % revenue); employee costs up.</li>
</ol>
</div>
<div id="summary" class="section level6">
<h6><strong>Summary</strong></h6>
<p>Natco is navigating Revlimid cliff with resilience (Q2 PAT ₹518 Cr, margins 46%), bolstered by Adcock (stable ₹135-150 Cr/Q PAT from Q3) and CHS demerger (2026 listing). Tailwinds from cash fortress, ROW ramps, and Semaglutide (domestic FY27 kickstart) outweigh headwinds like competition/FDA notes. Growth hinges on Para IV launches (FY27-28 inflection); FY26 PAT ~₹1,300 Cr guided. <strong>Rating Outlook</strong>: Positive (Buy/Hold for pipeline believers); risks tilted to execution/regulatory. Target multiples: 30-35x FY27 EPS on base + upside. Monitor FDA response and Q3 results for Revlimid reality.</p>
<p><em>Disclaimer</em>: Not investment advice; based solely on provided docs. Consult professionals.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
